Decisions around HIV treatment in 2015: Seven ways to fail, derail or prevail

In this issue brief, we review trends in generic competition and intellectual property (IP) licensing for key antiretroviral drugs. 

We then outline seven momentous decisions to be made in 2015 that will largely determine whether ART will be affordable, available and robust for the next 15 years of treatment scale-up to all people living with HIV.

Finally, we take stock of the current state of the ARV market with a snapshot of ARV prices for select second- and third-line ARV medicines by originator and generic manufacturers.

Additional publications in the Untangling the Web report series are available here.

Learn more about MSF’s work to improve access to lifesaving HIV treatment.